14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Thermodilution vs Estimated Fick Cardiac Output Measurement in Clinical Practice : An Analysis of Mortality From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (VA CART) Program and Vanderbilt University

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          Which commonly applied method to measure cardiac output, thermodilution or Fick using estimated oxygen consumption, performs better in routine clinical practice?

          Findings

          Among more than 15 000 adults in this cohort study who underwent right heart catheterization, thermodilution and estimated Fick cardiac output measurements agreed poorly, with estimates differing by greater than 20% in well over one-third of patients. Thermodilution estimates of cardiac output were more strongly associated with mortality than estimated Fick cardiac output estimates.

          Meaning

          Thermodilution and estimated Fick cardiac output estimates should not be considered interchangeable; thermodilution is preferable for most situations in clinical practice.

          Abstract

          Importance

          Thermodilution (Td) and estimated oxygen uptake Fick (eFick) methods are widely used to measure cardiac output (CO). They are often used interchangeably to make critical clinical decisions, yet few studies have compared these approaches as applied in medical practice.

          Objectives

          To assess agreement between Td and eFick CO and to compare how well these methods predict mortality.

          Design, Setting, and Participants

          This investigation was a retrospective cohort study with up to 1 year of follow-up. The study used data from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (VA CART) program. The findings were corroborated in a cohort of patients cared for at Vanderbilt University, an academic referral center. Participants were more than 15 000 adults who underwent right heart catheterization, including 12 232 in the Veterans Affairs cohort between October 1, 2007, and September 30, 2013, and 3391 in the Vanderbilt cohort between January 1, 1998, and December 31, 2014.

          Exposures

          A single cardiac catheterization was performed on each patient with CO estimated by both Td and eFick methods. Cardiac output was indexed to body surface area (cardiac index [CI]) for all analyses.

          Main Outcomes and Measures

          All-cause mortality over 90 days and 1 year after catheterization.

          Results

          Among 12 232 VA patients (mean [SD] age, 66.4 [9.9] years; 3.3% female) who underwent right heart catheterization in this cohort study, Td and eFick CI estimates correlated modestly ( r = 0.65). There was minimal mean difference (eFick minus Td = −0.02 L/min/m 2, or −0.4%) but wide 95% limits of agreement between methods (−1.3 to 1.3 L/min/m 2, or −50.1% to 49.4%). Estimates differed by greater than 20% for 38.1% of patients. Low Td CI (<2.2 L/min/m 2 compared with normal CI of 2.2-4.0 L/min/m 2) more strongly predicted mortality than low eFick CI at 90 days (Td hazard ratio [HR], 1.71; 95% CI, 1.47-1.99; χ 2 = 49.5 vs eFick HR, 1.42; 95% CI, 1.22-1.64; χ 2 = 20.7) and 1 year (Td HR, 1.53; 95% CI, 1.39-1.69; χ 2 = 71.5 vs eFick HR, 1.35; 1.22-1.49; χ 2 = 35.2). Patients with a normal CI by both methods had 12.3% 1-year mortality. There was no significant additional risk for patients with a normal Td CI but a low eFick CI (12.9%, P = .51), whereas a low Td CI but normal eFick CI was associated with higher mortality (15.4%, P = .001). The results from the Vanderbilt cohort were similar in the context of a more balanced sex distribution (46.6% female).

          Conclusions and Relevance

          There is only modest agreement between Td and eFick CI estimates. Thermodilution CI better predicts mortality and should be favored over eFick in clinical practice.

          Abstract

          This cohort study assesses agreement between thermodilution and estimated Fick cardiac output and compares how well these methods predict mortality.

          Related collections

          Author and article information

          Journal
          JAMA Cardiol
          JAMA Cardiol
          JAMA Cardiol
          JAMA Cardiology
          American Medical Association
          2380-6583
          2380-6591
          6 September 2017
          18 October 2017
          October 2017
          18 October 2018
          : 2
          : 10
          : 1090-1099
          Affiliations
          [1 ]Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
          [2 ]Department of Cardiology, Boston Children’s Hospital, Boston, Massachusetts
          [3 ]Veterans Affairs Eastern Colorado Health Care System, Denver
          [4 ]Veterans Affairs Boston Healthcare System, Boston, Massachusetts
          [5 ]Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
          [6 ]Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University Medical Center, Nashville, Tennessee
          [7 ]University of Colorado School of Medicine, Denver
          [8 ]Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
          [9 ]Department of Biostatistics, Vanderbilt University, Nashville, Tennessee
          [10 ]Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
          [11 ]Division of Cardiology, Department of Medicine, Northwestern University, Chicago, Illinois
          [12 ]Providence Veterans Affairs Medical Center, Providence, Rhode Island
          [13 ]Alpert Medical School of Brown University, Providence, Rhode Island
          [14 ]Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston
          Author notes
          Article Information
          Accepted for Publication: July 12, 2017.
          Corresponding Author: Alexander R. Opotowsky, MD, MPH, Department of Cardiology, Boston Children’s Hospital, 300 Longwood Ave, Boston, MA 02115 ( alexander.opotowsky@ 123456cardio.chboston.org ).
          Published Online: September 6, 2017. doi:10.1001/jamacardio.2017.2945
          Author Contributions: Drs Brittain and Maddox had full access to all of the data (for the Vanderbilt cohort and the Veterans Affairs Clinical Assessment, Reporting, and Tracking [VA CART] cohort, respectively) in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
          Study concept and design: Opotowsky, Maron, Brittain, Maddox, Wertheim, Tedford.
          Acquisition, analysis, or interpretation of data: All authors.
          Drafting of the manuscript: Opotowsky, Maron, Brittain, Maddox, Wertheim, Tedford.
          Critical revision of the manuscript for important intellectual content: All authors.
          Statistical analysis: Opotowsky, Hess, Brittain, Barón, Xu, Tedford.
          Obtained funding: Maron, Maddox.
          Administrative, technical, or material support: Opotowsky, Maron, Brittain, Maddox, Assad, Tedford.
          Study supervision: Opotowsky, Maron, Barón, Maddox, Tedford.
          Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Opotowsky reported investigator-initiated research supported by Actelion Pharmaceuticals and Roche Diagnostics. Dr Maron reported investigator-initiated research supported by Gilead Sciences Inc. Dr Brittain reported investigator-initiated research supported by Gilead Sciences Inc. Dr Maddox reported being national director of the Veterans Affairs Clinical Assessment, Reporting, and Tracking (VA CART) program. Dr Choudhary reported investigator-initiated research supported by Novartis. No other disclosures were reported.
          Funding/Support: Dr Opotowsky is supported by the Dunlevie Family Fund and by grant 17IRG33370023 from the American Heart Association. Dr Maron is supported by grant 1K08HL11207-01A1 from the National Institutes of Health, grant 15GRNT25080016 from the American Heart Association, the Pulmonary Hypertension Association, and The Cardiovascular Medical Research and Education Fund. Dr Brittain is supported by grant 13FTF16070002 from the American Heart Association. Dr Choudhary is supported by grant R01HL128661 from the National Institutes of Health.
          Role of the Funder/Sponsor: None of the funding organizations were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
          Additional Contributions: At Vanderbilt University, Quinn S. Wells, MD, and Eric H. Farber-Eger, BS, contributed to the development of the hemodynamic database. No compensation was received.
          Article
          PMC5710449 PMC5710449 5710449 hoi170044
          10.1001/jamacardio.2017.2945
          5710449
          28877293
          5925117d-b639-4e2a-9fbe-7bdac00709db
          Copyright 2017 American Medical Association. All Rights Reserved.
          History
          : 26 April 2017
          : 11 July 2017
          : 12 July 2017
          Categories
          Research
          Research
          Original Investigation
          Online First

          Comments

          Comment on this article